Relmada Therapeutics, Inc. (RLMD)

3.8300 +0.1300 (+3.51%) At close: 04:00PM EDT

Relmada Therapeutics, Inc.

2222 Ponce de Leon Boulevard
Floor 3
Coral Gables, FL 33134
United States
786-629-1376
https://www.relmada.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 20

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Sergio Traversa M.B.A., Pharm.D.	CEO & Director	1.79M	N/A	1960
Mr. Maged S. Shenouda M.B.A., R.Ph.	Chief Financial Officer	1.01M	N/A	1964
Mr. Charles S. Ence CPA, M.B.A.	Chief Accounting & Compliance Officer	995.03k	N/A	1965
Dr. Paolo Manfredi M.D., Ph.D.	Chief Scientific Officer	N/A	N/A	1962
Ms. Gina DiGuglielmo	VP & Head of Clinical Operations	N/A	N/A	N/A
Dr. Marco Pappagallo M.D.	Chief Clinical Officer	N/A	N/A	1959
Mr. John Hixon	Head of Commercial	N/A	N/A	N/A
Dr. Andrew Cutler	Senior Clinical Development Advisor	N/A	N/A	N/A
Dr. Richard M. Mangano	Consultant	N/A	N/A	1950

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

Corporate Governance

Relmada Therapeutics, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 9. The pillar scores are Audit: 6; Board: 10; Shareholder Rights: 4; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.